Oral Contrast: Worth the Diagnostic Benefit?

Article

When faced with the possibility of missed findings, would patients generally agree to consuming oral contrasts?

Most outpatients would accept drinking oral contrast material if it has diagnostic benefit, according to a study published in the Journal of the American College of Radiology.

Researchers from University of Michigan in Ann Arbor performed a prospective survey to determine how patients valued the use of oral contrast material when undergoing abdominopelvic CT.

A total of 218 patients completed the survey, in which the subjects were given a hypothetical choice to not drink oral contrast. Eighty-nine percent of the subjects (193 patients) stated that they would always drink the contrast for fear of missing an important finding, and only 2% (5 patients) stated that they would never drink it regardless of risk.

Nine percent (20 patients) said that the decision to drink oral contrast would depend on the level of risk, with 8% (18 patients) indicating that they would accept a 0.01% to 1.00% risk for missing an important finding if they did not have to drink oral contrast.

The researchers also asked about the tolerability of the oral contrast; 55% (120 patients) rated the oral contrast taste as tolerable and 10% (21 patients) rated it bad or terrible.

Thirty-six subjects experienced concern or unease when they learned that they had to drink oral contrast:

8 minimal concern or unease

15 mild

10 moderate

3 extreme

Thirty-six patients experienced oral contrast–induced nausea or abdominal discomfort:

10 minimal

15 mild

10 moderate

1 extreme

The researchers concluded that most patients will drink oral contrast if it has any diagnostic benefit.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.